Advertisement

 

 

Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.

Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.
Author Information (click to view)

White M, Freistaedter A, Jones GJB, Zervos E, Roper RL,


White M, Freistaedter A, Jones GJB, Zervos E, Roper RL, (click to view)

White M, Freistaedter A, Jones GJB, Zervos E, Roper RL,

Advertisement

PloS one 2018 02 2313(2) e0193131 doi 10.1371/journal.pone.0193131
Abstract

Pancreatic cancer is the 5th leading cause of cancer deaths, and there are no effective treatments. We developed a poxvirus platform vaccine with improved immunogenicity and inserted the mesothelin gene to create an anti-mesothelin cancer vaccine. Mesothelin expression is mostly restricted to tumors in adult mammals and thus may be a good target for cancer treatment. We show here that the modified vaccinia virus Ankara (MVA) virus expressing mesothelin and the enhanced MVA virus missing the immunosuppressive A35 gene and expressing mesothelin were both safe in mice and were able to induce IFN-gamma secreting T cells in response to mesothelin expressing tumor cells. In addition, the MVA virus has oncolytic properties in vitro as it can replicate in and kill Panc02 pancreatic adenocarcinoma cell line tumor cells, even though it is unable to replicate in most mammalian cells. Deletion of the A35 gene in MVA improved T cell responses as expected. However, we were unable to demonstrate inhibition of Panc02 tumor growth in immunocompetent mice with pre-vaccination of mice, boosts, or even intratumoral injections of the recombinant viruses. Vaccine efficacy may be limited by shedding of mesothelin from tumor cells thus creating a protective screen from the immune system.

Submit a Comment

Your email address will not be published. Required fields are marked *

15 − 9 =

[ HIDE/SHOW ]